Levi & Korsinsky, LLP announces that a ABMD class action lawsuit has been commenced on behalf of investors who purchased Abiomed, Inc. (ABMD) securities between January 31, 2019 and July 31, 2019. For more on the Abiomed Class Action please contact us today.

According to the Abiomed lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Abiomed’s revenue growth was in decline; (2) the Company did not have a sufficient plan in place to stem its declining revenue growth; (3) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE ABMD CLASS ACTION, VISIT: https://www.zlk.com/pslra-1/abiomed-inc-loss-form?wire=3

If you suffered a loss in Abiomed you have until October 7, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com